AMPAC Fine Chemicals Merged into New SK Holdings CMO
The new CMO combines SK Biotek in Korea, SK Biotek in Ireland, and AMPAC Fine Chemicals in the US to form SK Pharmteco.
SK Holdings, the holding company of South Korea's SK Group, announced it has combined SK Biotek in Korea, SK Biotek in Ireland, and AMPAC Fine Chemicals (AFC) in the United States to form SK Pharmteco, a new Sacramento, CA-based contract manufacturing organization (CMO) for pharmaceutical customers. The company will be headed by Aslam Malik, former CEO of AFC, as CEO.
"The creation of Pharmteco provides an excellent base upon which we will grow our global CMO business," said Malik in a Sept. 16, 2019 press release. "We are grateful for the strong support of SK Holdings and with our demonstrated Quality, six production plants, one analytical testing facility, and a wide array of enabling technologies, we are able to offer our unique value proposition to customers on an expanded global scale.”
According to the press release, SK Pharmteco has a CMO production capacity of over 1000 m3 with plans to expand within the next few years.
Source: AFC
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
